NASDAQ:RTRX - Retrophin Stock Price, Forecast & News

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

Retrophin Inc (NASDAQ:RTRX) posted its earnings results on Monday, February, 24th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.01. The biopharmaceutical company earned $46.69 million during the quarter, compared to analyst estimates of $46.60 million. Retrophin had a negative net margin of 83.51% and a negative return on equity of 56.87%. The business's revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. View Retrophin's Earnings History.

Retrophin is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Retrophin.

Retrophin updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $175-175 million, compared to the consensus revenue estimate of $173.75 million.

8 Wall Street analysts have issued 12-month price objectives for Retrophin's shares. Their forecasts range from $19.00 to $38.00. On average, they expect Retrophin's share price to reach $29.57 in the next year. This suggests a possible upside of 90.9% from the stock's current price. View Analyst Price Targets for Retrophin.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.

News articles about RTRX stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Retrophin earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Retrophin.

Retrophin saw a increase in short interest in February. As of February 14th, there was short interest totalling 4,440,000 shares, an increase of 10.2% from the January 30th total of 4,030,000 shares. Based on an average daily trading volume, of 389,100 shares, the days-to-cover ratio is presently 11.4 days. Approximately 10.8% of the shares of the company are sold short. View Retrophin's Current Options Chain.

Some companies that are related to Retrophin include PPD (SDGR), Apellis Pharmaceuticals (APLS), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), SAGE Therapeutics (SAGE), ArQule (ARQL), Uniqure (QURE), Principia Biopharma (PRNB), Synthorx (THOR), Ra Pharmaceuticals (RARX), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), Insmed (INSM), Forty Seven (FTSV) and Cambrex (CBM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Retrophin investors own include CVS Health (CVS), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), Intercept Pharmaceuticals (ICPT), Novavax (NVAX), Omeros (OMER), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO) and Exelixis (EXEL).

Retrophin's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.90%), Perceptive Advisors LLC (6.73%), State Street Corp (4.05%), Bank of America Corp DE (2.94%), Renaissance Technologies LLC (1.90%) and Jacobs Levy Equity Management Inc. (1.45%). Company insiders that own Retrophin stock include Elizabeth E Reed, Eric M Dube, Laura Clague, Neil F Mcfarlane, Noah L Rosenberg, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.

RTRX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Perceptive Advisors LLC, UBS Group AG, Rafferty Asset Management LLC, Oak Ridge Investments LLC, Cubist Systematic Strategies LLC, Strs Ohio and Altshuler Shaham Ltd. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Eric M Dube, Laura Clague, Neil F Mcfarlane, Noah L Rosenberg, Steve Aselage and William E Rote. View Insider Buying and Selling for Retrophin.

RTRX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Jacobs Levy Equity Management Inc., Schonfeld Strategic Advisors LLC, Renaissance Technologies LLC, Prudential Financial Inc., Bank of America Corp DE, Panagora Asset Management Inc. and Oxford Asset Management LLP. View Insider Buying and Selling for Retrophin.

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RTRX stock can currently be purchased for approximately $15.49.

Retrophin has a market capitalization of $667.87 million and generates $175.34 million in revenue each year. The biopharmaceutical company earns $-102,680,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. Retrophin employs 214 workers across the globe.View Additional Information About Retrophin.

The official website for Retrophin is http://www.retrophin.com/.

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]